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Abstract
Background: The Study of Aldesleukin with and without antiretroviral therapy (STALWART) evaluated whether intermittent
interleukin-2 (IL-2) alone or with antiretroviral therapy (ART) around IL-2 cycles increased CD4+ counts compared to no
therapy.
Methodology: Participants not on continuous ART with $300 CD4+ cells/mm3 were randomized to: no treatment; IL-2 for 5
consecutive days every 8 weeks for 3 cycles; or the same IL-2 regimen with 10 days of ART administered around each IL-2
cycle. CD4+ counts, HIV RNA, and HIV progression events were collected monthly.
Principal Findings: A total of 267 participants were randomized. At week 32, the mean CD4+ count was 134 cells greater in
the IL-2 alone group (p,0.001), and 133 cells greater in the IL-2 plus ART group (p,0.001) compared to the no therapy
group. Twelve participants in the IL-2 groups compared to 1 participant in the group assigned to no therapy experienced an
opportunistic event or died (HR 5.84, CI: 0.59 to 43.57; p = 0.009).
Conclusions: IL-2 alone or with peri-cycle HAART increases CD4+ counts but was associated with a greater number of
opportunistic events or deaths compared to no therapy. These results call into question the immunoprotective significance
of IL-2-induced CD4+ cells.
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Introduction
Antiretroviral therapy (ART) has led to significant suppression
of HIV replication and improvement in both morbidity and
mortality in patients with HIV-infection [1–3]. However, despite
maximal viral suppression, viral eradication has not been achieved
and viremia recurs in patients after treatment interruption [4–6].
Moreover, ART therapy is associated with significant toxicities,
important interactions with other medications, difficulties in
maintaining rigorous adherence, and its efficacy is limited by the
emergence of drug resistant HIV variants [7–9]. Once ART has
been started, lifelong therapy is required since treatment
interruptions are associated with an increased risk of disease
progression or death [10]. These limitations of ART have
underscored the need to explore adjuvant or alternative
therapeutic strategies for the treatment of HIV infection.
A number of randomized controlled trials have shown that the
use of recombinant interleukin-2 (IL-2) with ART leads to
significant and sustained increases in CD4+ counts in HIV-infected
patients [11–22]. Although the use of IL-2 with antiretrovirals in
the pre-ART era was associated with transient rises in plasma HIV
RNA levels in some study participants, no clinical trial of IL-2 in
HIV-infected patients has demonstrated a significant sustained
increase in either plasma HIV RNA or intracellular HIV DNA in
IL-2 recipients compared to controls. In fact, one randomized
study actually showed a larger decrease in viral load after one year
in participants given IL-2 and ART compared to those who
received ART alone [22]. Similarly, a pooled analysis of long-term
follow-up data from 3 randomized controlled trials showed that IL-
2 used with combination ART produced significant decreases in
viral load after a median of 30 months compared to ART alone
[23]. While the success observed in increasing CD4+ counts
without increasing viral load suggests IL-2 may be an effective
strategy to complement the effects of ART in HIV-infected
patients, it also raises the question of whether IL-2 can be used to
maintain CD4+ counts while sparing the use of ART.
One small pilot trial, the United Kingdom Vanguard Study,
showed that IL-2 used in the absence of concomitant ART
boosted CD4+ counts in patients with early HIV disease and had
no significant effect on viral load [24]. While that study provided
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promising data regarding the potential benefit and safety of IL-2
monotherapy, a relatively blunted CD4+ count response was
observed when compared to results from three concurrent IL-2
studies that used IL-2 in combination with ART [16,17,23]. The
average increase from baseline mean CD4+ count in the IL-2-
treated group in the United Kingdom Vanguard Study was +129
compared to +13 cells/mm3 in the no IL-2 or ART group. In
comparison, a meta-analysis showed the average increases from
baseline in the IL-2 and ART-treated groups in the three other
trials was +417 compared to +77 cells/mm3 in the ART alone
groups [23,24]. The reasons for this blunted CD4+ response to IL-
2 are unknown, but one hypothesis is that ART combined with IL-
2 has a synergistic effect to increase CD4+ count. This raises the
possibility that antiretrovirals administered during the IL-2 cycle
may yield a more robust immunologic response while sparing the
adverse effects of continuous ART.
STALWART was designed to evaluate the safety and immu-
nologic and virologic effects of intermittent IL-2 in asymptomatic,
HIV-infected patients who did not meet criteria for initiation of
ART. This study tested the hypothesis that intervention at an early
stage of HIV infection with intermittent IL-2 therapy either alone
or with peri-cycle ART would maintain or increase CD4+ counts
compared to controls receiving neither ART nor IL-2. Concurrent
with the STALWART study, two phase III trials were evaluating
the clinical efficacy of intermittent IL-2 plus ART compared to
ART alone in approximately 6,000 patients with HIV infection:
ESPRIT (Evaluation of Subcutaneous ProleukinH in a Random-
ized International Trial) and SILCAAT (Subcutaneous Recombi-
nant IL-2 in HIV-Infected Patients with Low CD4+ Counts under
Active Antiretroviral Therapy). Both studies demonstrated that IL-
2 in combination with continuous antiretrovirals did not result in a
decreased incidence of a new or recurrent HIV disease progression
event including death compared to ART alone [25,26]. Based
upon these results, IL-2 administration was halted in the
STALWART study and safety and efficacy data were unblinded.
Methods
Study Design
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. STALWART was an international, multi-site, phase II
open label randomized controlled study. Patients who met
enrollment criteria were randomized in a 1:1:1 ratio to one of
three groups: no therapy (control), IL-2 alone (IL-2), or IL-2 with
peri-cycle ART (IL-2+ART). Randomization was performed using
random permuted blocks stratified by individual clinical site. The
random allocation sequence was generated centrally for each site.
Sites accessed the randomization allocation sequence via the study
website and the sequence was concealed until interventions were
assigned. Dosing with IL-2 commenced at a dose of 7.5 million
international units (MIU) administered by subcutaneous injection
twice daily for a 5-day cycle. Dose reductions were permitted in 1.5
or 3.0 MIU/dose decrements. Both groups assigned to IL-2 were to
receive a minimum of 3 IL-2 cycles separated by an interval of 8
weeks with additional cycles permitted at clinician discretion.
The choice of peri-cycle ART regimens in the IL-2+ART group
was at the discretion of the site investigator, but regimens were
required to consist of at least 1 protease inhibitor and 2 nucleoside
or nucleotide reverse transcriptase inhibitors. Drug doses and
schedules were determined according to treatment guidelines and
package inserts. Because of possible hypersensitivity reactions with
intermittent use of abacavir and drug resistance associated with
intermittent use of NNRTIs, these drugs were excluded from the
study. Participants in the IL-2+ART group commenced ART
within 1 week of randomization and received an initial protocol-
required 7–21 consecutive day course of antiretrovirals prior to the
first IL-2 cycle. For subsequent cycles, ART was commenced 3
days prior to the initiation of IL-2 dosing, continued through the
IL-2 cycle, and was stopped 2 days after IL-2 administration for a
maximum of 10 days of ART around each cycle. Investigators
could recommend that participants in any assigned group
commence continuous ART at any time, and participants could
independently decide to commence continuous ART for any
reason. The primary outcome measure was the mean change in
CD4+ count from baseline to week 32. Secondary outcome
measures included grade 3 or 4 clinical events, mean change in
plasma viral load from baseline to week 32, initiation of
continuous antiretrovirals, and the development of HIV-1 drug
resistance mutations in the IL-2+ART group.
The study was originally designed with a target sample size of
480 participants based on 80% power to detect a 50 to 75 cells/
mm3 difference for each of the 3 planned pair-wise comparisons of
the CD4+ count change. A 50 to 75 cell difference in CD4+ cell
count was chosen because it was felt differences of that size would
be clinically important to detect, and could influence how ART
was used with IL-2. Due to a low rate of accrual and the
anticipated closure of the two phase 3 IL-2 studies ESPRIT and
SILCAAT, enrollment in STALWART was closed in June 2008.
After ESPRIT and SILCAAT demonstrated that IL-2 in
combination with continuous antiretrovirals did not result in a
decreased incidence of a new or recurrent HIV disease progression
event including death compared to antiretrovirals alone, IL-2
administration was halted in STALWART, and safety and efficacy
data were unblinded. Follow-up continued through a common
closing date of February 28, 2009 when all participants had
completed their week 32 visit evaluations.
Study Population
Eligible participants were at least 18 years of age, had
documented HIV-infection, a CD4+ count $300 cells/mm3,
and were antiretroviral naı¨ve or had not received ART for at least
one year prior to randomization. Exclusion criteria included
significant renal, hepatic, gastrointestinal, central nervous system
or hematologic disorders, or any history of autoimmune or
inflammatory disease. Local Ethics Committee/Institutional
Review Boards approved the study and written informed consent
was obtained from all participants.
Assessments
Study participants were required to have negative pregnancy tests
and complete blood counts and serum chemistries within protocol-
defined acceptable ranges, including hemoglobin levels above
10 gm/dL, granulocyte counts above 1000 cells/mm3 and AST
and ALT below 5 times the upper limit of normal. All participants
were seen at least monthly during the first 32 weeks of the study and
at least every 4 months thereafter. Medical and drug histories were
taken at each scheduled visit and CD4+ counts and HIV RNA, both
performed locally by a laboratory participating in a certified quality
assurance program, were measured. Complete blood counts and
chemistries were performed at the beginning and during each IL-2
cycle. Participants receiving IL-2+ART had blood drawn during
their third IL-2 cycle for HIV resistance genotyping (TruGene HIV-
1 Genotyping Assay; Siemens Medical Solutions Diagnostics,
Tarrytown, New York, USA). For those samples that demonstrated
major antiretroviral resistance mutations as defined by the
International Aids Society-USA Drug Resistance Mutations Group
[27], stored plasma from their first cycle was sent for HIV
STALWART Study
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genotyping to determine whether the mutations were present at
baseline or had developed during the course of the study. Source
documentation was provided by sites for opportunistic diseases and
deaths that occurred during the study. Adverse clinical events
(excluding opportunistic disease) were graded by site investigators
using a standard NIAID Division of AIDS toxicity table. Grade 3 or
4 adverse events were reported for all 3 treatment groups for the
duration of the trial, irrespective of perceived relationship to IL-2 or
ART; these events were coded centrally using the Medical
Dictionary for Regulatory Activities (MedDRA, version 12.0) by a
nurse who was blinded to study treatment.
Interim Safety and Efficacy Monitoring
An independent data and safety monitoring committee
reviewed interim analyses of primary and secondary outcomes as
well as safety at least annually.
Figure 1. STALWART study design and CONSORT flow diagram.
doi:10.1371/journal.pone.0009334.g001
STALWART Study
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Statistical Analysis
Statistical analysis was performed using SAS software, version
9.1. Unless otherwise indicated, all analyses are intent-to-treat, and
the p-values shown are two-sided.
The primary outcome, change in CD4+ count from baseline to
Week 32, was analyzed using analysis of variance stratified by
geographic region (7 strata total). All patients with data available
at week 32 were included and baseline CD4+ cell count was
included in the model as a covariate. An alpha level of .017 was
pre-specified to control for type I error, and the 95% confidence
intervals cited are adjusted for the 3 pairwise comparisons. All
other analyses are presented unadjusted for multiple compari-
sons, using a nominal .05 level of significance. Stratified analysis
of variance was also used to analyze HIV-RNA (log10
transformed). Time-to-event methods (stratified Cox proportional
hazards models and Kaplan Meier survival curves) were used to
analyze the incidence of adverse events and initiation of
continuous ART. For participants who were event-free, follow-
up time was censored at February 28, 2009 or on the date of loss
to follow up, whichever occurred earlier. Hazard ratios are shown
unadjusted.
Results
Study Population
From November 2005 to June 2008, 267 participants were
randomized from 36 sites in 11 countries: 91 to the control group,
89 to IL-2, 87 to IL-2+ART (figure 1). The baseline median CD4+
count was 419 cells/mm3, and median HIV RNA was
approximately 22,000 copies. Seventy-nine percent of participants
were antiretroviral naı¨ve. Baseline characteristics were similar
across assigned treatment groups (table 1).
Table 1. Baseline characteristics by treatment group.
IL-2 IL-2+ART Control Total
Age (years)
Median 35 35 36 36
Interquartile range 30–44
Gender (% female) 19.1 14.9 17.6 17.2
Race (%)
Asian 24.7 26.4 24.2 25.1
Black 4.5 4.6 8.8 6.0
White/other 70.8 69.0 67.0 68.9
CD4+ count (cells/mm3)
Median 399 425 432 419
Interquartile range 359–512
HIV-RNA (copies)
Median 23,508 21,881 24,328 22,384
Interquartile range 7,189–61,169
Medication Use and History
Antiretroviral (ART) naı¨ve (%) 76.4 87.4 72.5 78.7
Months since last ART use* (median) 36.9 28.9 32.0 21.3
Current OI prophylaxis use (%) 3.4 2.3 2.2 2.6
Likely mode of HIV transmission** (%)
Person of same sex 60.7 56.3 61.5 59.6
Person of opposite sex 38.2 41.4 37.4 39.0
Injection drug use 2.2 4.6 0.0 2.2
Blood products 1.1 1.1 0.0 0.7
Other or unknown 2.2 2.3 2.2 2.2
Hepatitis Status (%)
Hepatitis B surface antigen positive 5.6 0.0 5.6 3.8
Hepatitis C antibody positive 5.7 5.7 7.8 6.4
BMI (kg/m2)
Median 23.5 23.2 23.6 23.4
Interquartile range 21.2–26.2
Total cholesterol (mg/dl)
Median 166 170 170 170
Interquartile range 147–196
*among antiretroviral experienced patients.
**more than one could be checked.
doi:10.1371/journal.pone.0009334.t001
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Use of IL-2 and Peri-Cycle-ART
Sixty-seven (75%) and 55 (63%) of participants in the IL-2 and
IL-2+ART groups received at least 3 cycles before 32 weeks. At
the third cycle, the mean total dose was 64.0 vs. 63.3 MIU,
respectively. The most commonly used peri-cycle ART regimens
included a combination of ritonavir boosted lopinavir, atazanavir,
or fosamprenavir with either zidovudine and lamivudine or
tenofovir and emtricitabine.
CD4+ Cell Count
The primary outcome of week-32 CD4+ count was available for
approximately 90% of living participants (figure 1). Figure 2 shows
the median CD4+ count of the 3 groups at follow-up visits. At week
32, control participants had a mean change in CD4+ count of -22
cells/mm3 compared to +114 for those receiving IL-2 alone and
+110 for those receiving IL-2+ART. Compared to the control
participants, the mean change from baseline in CD4+ count (after
adjustment for baseline CD4+ count) was higher by 134 cells/mm3
(95% CI: 70 to 198, p,0.001) in participants receiving IL-2 alone
and higher by 133 cells/mm3 (95% CI: 68 to 199, p,0.001) in
those receiving IL-2+ART. There was no difference between the
two IL-2 groups (20.5 cells/mm3; 95% CI: 267 to 66).
HIV RNA Level
At week 32, participants receiving no IL-2 or ART had a mean
change in log10 HIV RNA of 20.40 compared to 20.07 for those
receiving IL-2 alone and 20.01 for those receiving IL-2+ART.
Compared to the control participants, the mean change from
baseline log10 viral load was +0.31 (95% CI: 0.08 to 0.55;
p = 0.009) in participants receiving IL-2 alone and +0.37 (95% CI:
0.13 to 0.61; p,0.003) in those receiving IL-2+ART. The
difference in HIV RNA between the two IL-2 groups was not
statistically significant (0.05; 95% CI: 20.19 to 0.29; p = 0.67).
Commencement of Continuous Antiretroviral Therapy
By the date of study closure, 34 participants assigned to no
therapy had commenced continuous ART compared with 23 in
the IL-2 alone and 14 in the IL-2+ART groups [figure 3(a)]. Using
the control group as reference, the hazard ratio for commencing
continuous ART was 0.58 (95% CI: 0.34 to 0.99; p = 0.048) for
the IL-2 group and 0.32 (95% CI: 0.17 to 0.62; p,0.001) for the
IL-2+ART group. The most common reason for starting
continuous ART in all three groups was a low or declining
CD4+ count.
Moderate or Severe Adverse Events
Compared to the control group where eight participants
experienced a moderate (grade 3) or severe (grade 4) event, 17
participants randomized to IL-2 alone [hazard ratio 2.60 (95% CI:
1.12 to 6.06; p = 0.03)] and 24 among those randomized to IL-
2+ART [hazard ratio 4.05, 95% CI: 1.81 to 9.05; (p,0.001)]
experienced at least one such event. As reported in previous
studies of IL-2, common IL-2-related toxicities included fever,
nausea, myalgias and rash. There was no statistically significant
difference in the risk of a grade 3 or 4 event between participants
receiving IL-2+ART versus those receiving IL-2 alone [hazard
ratio 1.56; 95% CI: 0.83 to 2.91; (p = 0.17)].
Genotyping Results
Fifty-four (62%) participants randomized to receive IL-2+ART
completed 3 cycles of IL-2 and had specimens available for
genotyping. Sequencing was successful in 47 participant samples.
Two participants were found to have detectable HIV resistance
mutations at cycle 3 (41L and 210W in one and 219Q in the
other). The same mutations were found in samples saved at the
end of cycle 1 from these patients, suggesting these TAMS were
present at study entry, or developed during the first cycle of IL-2
administration.
Clinical Outcomes
Table 2 shows opportunistic events and deaths by randomized
group. The median follow-up was approximately 19 months. Five
participants in the IL-2 alone group and 7 participants in the IL-
2+ART group experienced an opportunistic event or died
compared to one participant in the group assigned to no therapy.
Compared to the control participants, the hazard ratio for
Figure 2. Median CD4+ cell count.
doi:10.1371/journal.pone.0009334.g002
STALWART Study
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Figure 3. Time to first use of continuous antiretroviral therapy and time to first opportunistic event or death.
doi:10.1371/journal.pone.0009334.g003
STALWART Study
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developing an opportunistic disease or death from any cause was
5.08 (95% CI: 0.59 to 43.57; p = 0.14) for those receiving IL-2
alone and 6.56 (95% CI: 0.80 to 53.62; p = 0.08) for those
receiving IL-2+ART. When the events in both IL-2 groups were
pooled and compared to events in control participants, the hazard
ratio was 5.84 (95% CI: 0.76 to 45.11; p = 0.09). [Figure 3(b).] The
hazard ratio for clinical events excluding the two deaths was 4.88
(CI = 0.62 to 38.3, p = 0.13). No participant who experienced an
event was on continuous ART when their event occurred.
Discussion
This is the largest clinical trial demonstrating that IL-2 alone in
asymptomatic HIV-infected patients produces significant increases
in CD4+ counts without changing plasma HIV RNA levels.
Clinical trials of IL-2 administered with continuous antiretrovirals
have demonstrated CD4+ count increases of 200 cells/mm3 or
greater from baseline after 3 cycles. The magnitude of the CD4+
count increase from baseline seen after 3 cycles in this study –
approximately 130 cells/mm3 at 32 weeks – was similar to that
found in other studies that have evaluated IL-2 without continuous
ART [24,28]. This study was the first to evaluate the addition of
peri-cycle ART to IL-2, and it was found that this strategy did not
increase CD4+ cell response compared to IL-2 alone. There are at
least 2 possible reasons why peri-cycle ART did not produce
increases similar to continuous ART. First, the viral suppression
afforded by peri-cycle ART may have been insufficient in duration
or degree to create an appropriate immunologic milieu for a
synergistic IL-2 response. Second, the greater increases in CD4+
count seen with IL-2 and continuous ART may not, in fact, be due
to synergy between these drugs but instead reflect a simple additive
effect of intermittent IL-2 and continuous ART-induced CD4+ cell
increases.
The control group showed a significantly larger decrease in
HIV RNA than either IL-2 group. When data were censored from
participants who started who started continuous ART, there were
no statistically significant changes in HIV RNA among the three
groups. However, this ad hoc analysis is not protected by
randomization and should be interpreted with caution.
Concurrent with the STALWART study, ESPRIT and
SILCAAT were two clinical trials designed to evaluate the clinical
efficacy of intermittent IL-2 plus continuous ART compared to
ART alone in approximately 6,000 participants with HIV
infection. Both studies demonstrated that, while IL-2 in combina-
tion with continuous ART did produce significant and sustained
increases in CD4+ cell counts, this did not result in a decreased
incidence of new or recurrent HIV disease progression events
including death compared to ART alone. Of concern, IL-2
recipients in STALWART had a greater number of opportunistic
diseases or deaths compared to controls that did not receive IL-2.
The relationship of IL-2 to the events seen in STALWART must
be interpreted cautiously. First, the overall number of events is
small. Second, of the 12 events in IL-2 recipients, 5 occurred in
participants who received only one cycle of IL-2, and another
event occurred in a participant who was randomized to but never
received IL-2. Nonetheless, the trend in clinical events observed in
STALWART is concerning in light of the results of ESPRIT and
SILCAAT that question the functionality of CD4+ cells induced by
IL-2. Specifically, these results suggest that CD4+ counts may no
longer serve as an accurate indicator of immune function in IL-2
recipients. In STALWART, the groups assigned to receive IL-2
started continuous ART less frequently than controls, and none of
the participants with clinical events were on continuous ART prior
to their event. Since a low CD4+ count was the most common
reason given for starting continuous ART, one hypothesis to
explain the greater number of clinical events in the IL-2 groups is
that the IL-2-induced elevations in CD4+ counts, taken at face
value, did not trigger the initiation of ART. Of note, another
clinical trial comparing IL-2 monotherapy to no intervention,
ANRS 119, also found that IL-2 recipients delayed ART initiation
compared to controls, but an increase in clinical events was not
observed: progression rates to AIDS or death were similar in the
IL-2 (8%) and control (9%) arms [28].
IL-2 has been shown to raise CD4+ counts by expansion as well
as increased survival of peripheral CD4+ cells [29], and it might be
helpful to differentiate these IL-2 expanded – and possibly
nonfunctional – cells in order to calculate a more accurate
surrogate marker for disease progression in patients who have
Table 2. Reported disease progression events.
List of Reported Opportunistic Events
Group Event No. cycles prior to event Prox. CD4 Study Day Event Dx Baseline CD4
IL-2 Toxoplasmosis 1 371 78 370
PCP 1 390 66 310
Tuberculosis 1 302 194 291
Tuberculosis 3 148 356 298
Bact. pneumonia initial 0 248 26 352
IL-2 + ART Non-Hodgkins lymphoma 4 311 540 290
Herpes zoster, multidermal 2 550 113 330
Bact. pneumonia initial 3 474 706 451
Bact. pneumonia initial 1 465 219 394
Candidiasis esophageal 3 524 687 408
Death, Motor Vehicle Accident 2 368 114 288
Death Coronary Atherosclerosis 1 438 48 382
Control Herpes zoster, multidermal . 548 236 466
doi:10.1371/journal.pone.0009334.t002
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received IL-2. For example, the CD4+ cells expanded in the setting
of IL-2 express increased levels of the alpha chain of the IL-2
receptor, CD25. Although this marker might be used to calculate a
CD4+ count that more accurately represents an IL-2 recipient’s
immunological status, it is unlikely that a study will be undertaken
to validate a new surrogate of immune status for this population.
Therefore, the results from this trial have implications for the
clinical management of patients who have received IL-2 since the
CD4+ count may not accurately reflect the immunological status of
these patients. First, in patients who have received IL-2 but who
are not on continuous ART, antiretroviral treatment should be
considered before these patients meet guideline-defined CD4+
criteria for commencing ART. Second, in those patients who have
received IL-2 and are on continuous ART, careful and timely
clinical evaluations should be undertaken if they present with
symptoms of opportunistic diseases even if these occur in the
setting of a high CD4+ count. If the IL-2 induced CD4+ count is
no longer clinically useful as a surrogate of immune function and
the duration of these CD4+ count increases is unknown, it would
be of value to prolong the follow-up of STALWART participants.
Therefore, in order to extend safety evaluations in the STAL-
WART cohort, participants will be offered an additional two years
of unblinded clinical follow up.
In summary, the STALWART study confirmed that IL-2
induces a significant increase in CD4+ count in HIV-infected
patients not receiving continuous ART, and demonstrated that the
magnitude of increase is not affected by the administration of short
courses of peri-cycle ART. The CD4+ increases led to a significant
delay in starting ART in IL-2 recipients, but this potential benefit
appears to be offset by a potential increase in risk of clinical events.
Taken together with the findings of ESPRIT and SILCAAT, this
calls into question the ability of these IL-2 induced CD4+ cells to
prevent opportunistic diseases.
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